Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

References for PMC Articles for PubMed (Select 21343146)

2.

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH; MOPH-TAVEG Investigators.

N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.

3.

Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells.

Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, Kwon DS, Addo MM, Brumme C, Routy JP, Little S, Jessen HK, Kelleher AD, Hecht FM, Sekaly RP, Rosenberg ES, Walker BD, Carrington M, Altfeld M.

J Virol. 2009 Aug;83(15):7641-8. doi: 10.1128/JVI.00182-09. Epub 2009 May 20.

4.

Use of predictive markers of HIV disease progression in vaccine trials.

Gurunathan S, Habib RE, Baglyos L, Meric C, Plotkin S, Dodet B, Corey L, Tartaglia J.

Vaccine. 2009 Mar 23;27(14):1997-2015. doi: 10.1016/j.vaccine.2009.01.039. Epub 2009 Feb 4. Review.

PMID:
19200450
5.

HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition.

Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, Rathod A, Block BL, Brumme ZL, Brumme CJ, Baker B, Rothchild AC, Li B, Trocha A, Cutrell E, Frahm N, Brander C, Toth I, Arts EJ, Allen TM, Walker BD.

J Virol. 2009 Mar;83(6):2743-55. doi: 10.1128/JVI.02265-08. Epub 2008 Dec 30. Erratum in: J Virol. 2009 Jun;83(11):5961.

6.

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR; Step Study Protocol Team.

Lancet. 2008 Nov 29;372(9653):1894-905. doi: 10.1016/S0140-6736(08)61592-5. Epub 2008 Nov 13.

7.

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN; Step Study Protocol Team.

Lancet. 2008 Nov 29;372(9653):1881-93. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.

8.

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA; International AIDS Society-USA.

JAMA. 2008 Aug 6;300(5):555-70. doi: 10.1001/jama.300.5.555.

PMID:
18677028
9.

Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women.

Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, Hernández-Aguado I, Meyer L, Porter K, del Amo J; CASCADE Collaboration.

Am J Epidemiol. 2008 Sep 1;168(5):532-40. doi: 10.1093/aje/kwn179. Epub 2008 Jul 28.

10.

Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection.

Brumme ZL, Brumme CJ, Carlson J, Streeck H, John M, Eichbaum Q, Block BL, Baker B, Kadie C, Markowitz M, Jessen H, Kelleher AD, Rosenberg E, Kaldor J, Yuki Y, Carrington M, Allen TM, Mallal S, Altfeld M, Heckerman D, Walker BD.

J Virol. 2008 Sep;82(18):9216-27. doi: 10.1128/JVI.01041-08. Epub 2008 Jul 9.

11.

Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells.

Streeck H, Brumme ZL, Anastario M, Cohen KW, Jolin JS, Meier A, Brumme CJ, Rosenberg ES, Alter G, Allen TM, Walker BD, Altfeld M.

PLoS Med. 2008 May 6;5(5):e100. doi: 10.1371/journal.pmed.0050100.

12.

Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E; Merck V520-016 Study Group.

Clin Infect Dis. 2008 Jun 1;46(11):1769-81. doi: 10.1086/587993.

13.

HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.

Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, McCune JM, Deeks SG.

J Virol. 2008 Jun;82(11):5398-407. doi: 10.1128/JVI.02176-07. Epub 2008 Mar 19.

14.

Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.

Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD.

J Infect Dis. 2008 Feb 15;197(4):563-71. doi: 10.1086/526786.

15.

Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype.

Harari A, Cellerai C, Bellutti Enders F, Köstler J, Codarri L, Tapia G, Boyman O, Castro E, Gaudieri S, James I, John M, Wagner R, Mallal S, Pantaleo G.

Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16233-8. Epub 2007 Oct 2.

16.

Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover.

Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, Asher TE, Samri A, Schnuriger A, Theodorou I, Costagliola D, Rouzioux C, Agut H, Marcelin AG, Douek D, Autran B, Appay V.

J Exp Med. 2007 Oct 1;204(10):2473-85. Epub 2007 Sep 24.

17.

Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication.

Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, Rinaldo CR, Craggs SL, Allgaier RL, Power KA, Kuntzen T, Tung CS, LaBute MX, Mueller SM, Harrer T, McMichael AJ, Goulder PJ, Aiken C, Brander C, Kelleher AD, Allen TM.

J Virol. 2007 Nov;81(22):12382-93. Epub 2007 Sep 5.

18.

A whole-genome association study of major determinants for host control of HIV-1.

Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith JP, Wyniger J, Descombes P, Antonarakis SE, Letvin NL, McMichael AJ, Haynes BF, Telenti A, Goldstein DB.

Science. 2007 Aug 17;317(5840):944-7. Epub 2007 Jul 19.

19.

HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1.

Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, Burgett N, Swartz ME, Yang A, Alter G, Yu XG, Meier A, Rockstroh JK, Allen TM, Jessen H, Rosenberg ES, Carrington M, Walker BD.

PLoS Med. 2006 Oct;3(10):e403.

20.

Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution.

Li B, Gladden AD, Altfeld M, Kaldor JM, Cooper DA, Kelleher AD, Allen TM.

J Virol. 2007 Jan;81(1):193-201. Epub 2006 Oct 25.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk